Bioactive Products
| A unique collection of 223 Neuroprotection natural compounds for high throughput screening (HTS) | ||
| Catalog No: | B72a21 | Neuroprotection Compound Library Screening Details |
| Size: | 1mg/well * 223 Compounds 2mg/well * 223 Compounds | |
| Cat. No. | Information |
| CFN99840 | Myricitrin Myricitrin exhibits hepatoprotective, anti-inflammatory,antioxidant, anti-allergic, antinociception, anxiolytic-like, and antipsychotic-like effects. Myricitrin can be used as a drug candidate for the treatment of cardiovascular diseases, by effectively protecting cells from ox-LDL-induced endothelial cell apoptosis and reducing atherosclerotic plaque formation. Myricitrin is also a nitric oxide (NO) and protein kinase C (PKC) inhibitor that has central nervous system activity. |
| CFN99909 | Tetramethylpyrazine Tetramethylpyrazine has antiinflammatory, analgesic, antioxidant, antiplatelet, antitumor, hepatoprotective, and antiapoptosis activities. Tetramethylpyrazine exerts neuroprotective effect against hypoxia, it inhibits CoCl2 -induced neurotoxicity through enhancement of Nrf2/GCLc/GSH and suppression of HIF1α/NOX2/ROS pathways. It targeted HSCs via PDGF-βR/NLRP3/caspase1 pathway. |
| CFN99912 | Asiaticoside Asiaticoside, a biochemical modulator, which has antioxidant, anti-inflammatory, antipyretic, anxiolytic-like, anti-gastric ulcers, hepatoprotective, and antidepressant-like effects, it also exhibits significant wound healing activity in normal as well as delayed healing models. Asiaticoside suppressed collagen expression and TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts. It and its derivatives can be regarded as reasonable candidates for a therapeutic Alzheimer's disease drug that protects neurons from Abeta toxicity. |
| CFN99913 | Madecassoside Madecassoside is a mechanism-based inhibitor of CYP2C19 and CYP3A4, which has antioxidant, anti-inflammatory, anti-apoptosis, wound-healing, and neuroprotective activities, It may have cardioprotective effects in LPS-mediated through inhibition of ERK, p38, and NF-κB activity, it inhibited the pro-inflammatory mediators, including COX-2 expression, PGE2 production, TNF-αand IL-6 levels and the up-regulation anti-inflammatory molecule IL-10. |
| CFN99858 | Loganin Loganin is a non-competitive inhibitor of BACE1 with IC50 of 47.97 μM an also inhibits AChE and BChE with IC50 values of 3.95 μM and 33.02 μM, respectively. Loganin has neuroprotective, anti-amnesic, anti-inflammatory and anti-shock effects, it also exhibits protective effects against hepatic injury and other diabetic complications associated with abnormal metabolic states and inflammation caused by oxidative stress and advanced glycation endproduct formation. Loganin can attenuate neuroinflammatory responses through the inactivation of NF-κB by NF-κB dependent inflammatory pathways and phosphorylation of MAPK in Aβ25-35-induced PC12 cells, and can protect against hydrogen peroxide-induced apoptosis by inhibiting phosphorylation of JNK, p38, and ERK 1/2 MAPKs in SH-SY5Y cells. |
